Blurbs

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Nektar Therapeutics (NKTR) and Alnylam Pharma (ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIXResearch Report), Nektar Therapeutics (NKTRResearch Report) and Alnylam Pharma (ALNYResearch Report).

Nurix Therapeutics (NRIX)

Needham analyst Gil Blum maintained a Buy rating on Nurix Therapeutics on October 7 and set a price target of $32.00. The company’s shares closed last Monday at $10.99, close to its 52-week low of $7.52.

According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -22.0% and a 28.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Crispr Therapeutics AG.

Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.50, which is a 286.4% upside from current levels. In a report issued on October 7, H.C. Wainwright also maintained a Buy rating on the stock with a $53.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Nektar Therapeutics (NKTR)

In a report issued on October 6, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $3.55, close to its 52-week low of $2.96.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.3% and a 33.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target.

Alnylam Pharma (ALNY)

In a report issued on October 7, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $430.00. The company’s shares closed last Monday at $186.82.

According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.7% and a 32.8% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $236.68, which is a 21.7% upside from current levels. In a report issued on October 3, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NRIX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More